July 18, 2022
Joppe Nieuwenhuis, Innovation Scout at Rejuveron Life Sciences, discusses his views about the future of longevity and rejuvenation research and how it will merge with current medical frameworks and systems. About Rejuveron Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding...
July 12, 2022
Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce that the first participant has been treated in Endogena Therapeutics’ phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). See Endogena’s full press release here. Rejuveron has a near-majority...
February 10, 2021
The Third Annual Longevity Therapeutics Summit brought together some of the biggest names translating longevity research into human patients. This is part three of our coverage of this conference; you can find part one here and part two here, and the final installment will be published shortly. Brian Culley – Lineage Cell Therapeutics Lineage Cell...
